Sensus Healthcare found using ticker (SRTS) have now 6 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 6 and 2.95 and has a mean target at 4.43. Now with the previous closing price of 3.36 this would imply there is a potential upside of 31.8%. There is a 50 day moving average of 3.13 and the 200 day MA is 2.9. The market capitalisation for the company is $57m. Find out more information at: http://www.sensushealthcare.com
Sensus Healthcare manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary robotic intraoperative radiation therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare was founded in 2010 and is headquartered in Boca Raton, Florida.
